Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice.
To assess the efficacy and safety of adalimumab in biologic naïve versus non-biologic naïve psoriasis patients. A retrospective multicenter study of patients with moderate-to-severe psoriasis treated uninterruptedly with adalimumab between 6 and 36 months. A total of 100 patients (52 men, 48 women; mean age 45.5 years; 90% plaque-type psoriasis) were included. Previous treatments included biologics in 53 and non-biologic modalities in 47. The mean (SD) start Psoriasis Area and Severity Index (PASI) score was 15.9 (11.1) (range 2-55). The median follow-up was 18 months (interquartile range 10-24 months). Sixteen weeks after the start of treatment, 94% of the patients presented PASI 75 response, 76% PASI 90, and 39% were in complete remission (PASI 100). Similar findings were obtained in the groups of biologic naïve and non-biologic naive patients. At the final visit, around 37% in all groups were in complete remission. At the end of the study, 74 patients continued treatment with adalimumab (43 [91.5%] in the biologic naïve group and 31 [58.5%] in the non-biologic naïve group, p<0.001). This study confirms the efficacy and safety of adalimumab for moderate-to-severe psoriasis without differences between biologic naïve and non-naïve patients.